Michael Aigner

5.0k total citations · 1 hit paper
81 papers, 1.4k citations indexed

About

Michael Aigner is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Michael Aigner has authored 81 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 30 papers in Immunology and 17 papers in Molecular Biology. Recurrent topics in Michael Aigner's work include CAR-T cell therapy research (29 papers), Immune Cell Function and Interaction (13 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Michael Aigner is often cited by papers focused on CAR-T cell therapy research (29 papers), Immune Cell Function and Interaction (13 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Michael Aigner collaborates with scholars based in Germany, Austria and Switzerland. Michael Aigner's co-authors include Andréas Mackensen, Simon Völkl, Stefanie Schaffer, Norbert Lehn, Ludwig Deml, Wulf Schneider‐Brachert, Georg Schett, Dimitrios Mougiakakos, Michael Rehli and Jürgen Miethlinger and has published in prestigious journals such as Nature Medicine, Nano Letters and Blood.

In The Last Decade

Michael Aigner

76 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

2025 15 citations Fabian Müller, Simon Völkl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Aigner Germany	22	588	469	440	173	136	81	1.4k
Keisuke Sakai Japan	25	567 1.0×	380 0.8×	753 1.7×	122 0.7×	147 1.1×	80	2.0k
Xing He China	16	546 0.9×	679 1.4×	455 1.0×	71 0.4×	102 0.8×	35	1.6k
Yasser M. El‐Sherbiny United Kingdom	24	1.1k 1.9×	341 0.7×	469 1.1×	139 0.8×	119 0.9×	66	2.0k
Eduardo Dávila United States	24	1.3k 2.2×	748 1.6×	674 1.5×	181 1.0×	114 0.8×	61	2.2k
Marius Strioga Lithuania	15	594 1.0×	279 0.6×	328 0.7×	301 1.7×	186 1.4×	21	1.6k
Juan Carlos Varela United States	21	496 0.8×	357 0.8×	287 0.7×	84 0.5×	67 0.5×	63	1.1k
Yutaka Kawano Japan	13	503 0.9×	298 0.6×	424 1.0×	189 1.1×	197 1.4×	52	1.7k
Adela R. Cardones United States	18	1.2k 2.0×	1.3k 2.8×	486 1.1×	132 0.8×	198 1.5×	61	2.3k
Toshiyuki Owaki Japan	17	959 1.6×	500 1.1×	202 0.5×	117 0.7×	106 0.8×	24	1.5k
David W. Griggs United States	22	336 0.6×	423 0.9×	993 2.3×	300 1.7×	250 1.8×	39	2.5k

Countries citing papers authored by Michael Aigner

Since Specialization

Citations

This map shows the geographic impact of Michael Aigner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Aigner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Aigner more than expected).

Fields of papers citing papers by Michael Aigner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Aigner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Aigner. The network helps show where Michael Aigner may publish in the future.

Co-authorship network of co-authors of Michael Aigner

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Aigner. A scholar is included among the top collaborators of Michael Aigner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Aigner. Michael Aigner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aigner, Michael, Katharina Zimmermann, Axel Schambach, et al.. (2025). Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets. HemaSphere. 9(12). e70279–e70279.

Reimann, Hannah, Kilian Schober, Johan Verhagen, et al.. (2023). Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains. Immunobiology. 228(5). 152720–152720. 1 indexed citations

Aigner, Michael, et al.. (2023). Influence of microstructure on degradation of cast graphitic high-speed steel. Wear. 522. 204702–204702. 8 indexed citations

Aigner, Michael, et al.. (2023). On the Performance and Surface Quality of Graphitic HSS Roll Grades at Tata Steel’s Direct Sheet Plant. 1 indexed citations

Müller, Fabian, Sebastian Boeltz, Simon Völkl, et al.. (2023). OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS. Annals of the Rheumatic Diseases. 82. 93–94. 11 indexed citations

Park, Sungha, et al.. (2023). POS0007 KYV-101, A FULLY HUMAN CD19 CAR T CELL GENERATED FROM AUTOIMMUNE PATIENT LYMPHOCYTES, DEMONSTRATES CAR-MEDIATED AND CD19-DEPENDENT ACTIVITY AGAINST AUTOLOGOUS B CELLS. Annals of the Rheumatic Diseases. 82. 208–209. 2 indexed citations

Müller, Fabian, Michael Aigner, Simon Völkl, et al.. (2023). Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Molecular Therapy — Methods & Clinical Development. 31. 101104–101104. 28 indexed citations

Müller, Fabian, Sebastian Boeltz, Johannes Knitza, et al.. (2023). POS1238 FIRST EVIDENCE FOR EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY ANTISYNTHETASE SYNDROME. Annals of the Rheumatic Diseases. 82. 957–958. 2 indexed citations

Kremer, Andreas E., Carsten Willam, Simon Völkl, et al.. (2021). Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity. European Journal of Immunology. 51(10). 2478–2484. 4 indexed citations

10.

Schaffer, Stefanie, Simon Völkl, Katrin Peter, et al.. (2019). Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA. Molecular Cancer Therapeutics. 19(2). 409–419. 25 indexed citations

11.

Aigner, Michael, Kai Hildner, Dimitrios Mougiakakos, et al.. (2019). Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity. Frontiers in Immunology. 10. 883–883. 30 indexed citations

12.

Gary, Regina, Michael Aigner, Stefanie Schaffer, et al.. (2018). Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. Journal of Translational Medicine. 16(1). 124–124. 13 indexed citations

13.

Aigner, Michael, et al.. (2017). Modeling and optimization of melt filtration systems in polymer recycling. AIP conference proceedings. 1914. 80004–80004. 5 indexed citations

14.

Aigner, Michael, et al.. (2014). Verifying the Melting Behavior in Single-Screw Plasticization Units Using a Novel Simulation Model and Experimental Method. International Polymer Processing. 29(5). 624–634. 7 indexed citations

15.

Hansen, Lars Hestbjerg, Hasan Tawamie, Yoshiko Murakami, et al.. (2013). Hypomorphic Mutations in PGAP2, Encoding a GPI-Anchor-Remodeling Protein, Cause Autosomal-Recessive Intellectual Disability. The American Journal of Human Genetics. 92(4). 575–583. 73 indexed citations

16.

Harre, Ulrike, Hildegard Keppeler, Natacha Ipseiz, et al.. (2012). Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity. 45(8). 612–619. 50 indexed citations

17.

Aigner, Michael, Julian Feulner, Stefanie Schaffer, et al.. (2012). T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 27(5). 1107–1115. 101 indexed citations

18.

Kellner, Christian, Harald Lanig, Michael Aigner, et al.. (2010). Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16. Journal of Immunotherapy. 33(6). 599–608. 66 indexed citations

19.

Ullrich, Evelyn, Michael Aigner, Simon Völkl, et al.. (2009). Advances in cellular therapy: 5th International Symposium on the clinical use of cellular products, 19 and 20 March 2009, Nürnberg, Germany. Cancer Immunology Immunotherapy. 59(11). 1745–1756. 1 indexed citations

20.

Paepke, Stefan, Gϋnter von Minckwitz, M. Kaufmann, et al.. (2003). Medikamentöse Prävention des Mammakarzinoms: eine Übersicht über die Literatur und den Stand in Deutschland. Zentralblatt für Gynäkologie. 125(9). 338–345. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact